Cytokinetics (NASDAQ:CYTK) Price Target Raised to $110.00

Cytokinetics (NASDAQ:CYTK) had its price objective boosted by Citizens Jmp from $105.00 to $110.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s target price suggests a potential upside of 44.32% from the stock’s current price.

Several other analysts have also recently weighed in on CYTK. JPMorgan Chase & Co. raised their price objective on shares of Cytokinetics from $92.00 to $97.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a report on Friday, July 17th. Morgan Stanley increased their price objective on Cytokinetics from $90.00 to $103.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Cytokinetics in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.10.

Cytokinetics Stock Down 6.3%

NASDAQ:CYTK traded down $5.15 during mid-day trading on Friday, hitting $76.22. 1,000,844 shares of the stock traded hands, compared to its average volume of 2,162,348. The business’s 50-day moving average price is $78.91 and its 200 day moving average price is $70.86. The company has a market cap of $9.48 billion, a PE ratio of -11.18 and a beta of 0.38. Cytokinetics has a 12-month low of $32.89 and a 12-month high of $88.31.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to the consensus estimate of $17.59 million. The firm’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same period in the previous year, the business earned ($1.12) earnings per share. Analysts anticipate that Cytokinetics will post -6.2 earnings per share for the current fiscal year.

Insider Transactions at Cytokinetics

In related news, EVP Sung Lee sold 1,112 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $87.79, for a total value of $97,622.48. Following the sale, the executive vice president directly owned 63,221 shares of the company’s stock, valued at $5,550,171.59. This represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $80.87, for a total value of $606,525.00. Following the sale, the chief executive officer directly owned 377,820 shares of the company’s stock, valued at $30,554,303.40. This represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 115,179 shares of company stock valued at $9,126,054 over the last three months. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Cytokinetics

Several institutional investors and hedge funds have recently made changes to their positions in CYTK. Millennium Management LLC boosted its stake in shares of Cytokinetics by 361.9% during the first quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company’s stock valued at $11,571,000 after purchasing an additional 225,576 shares during the period. Cetera Investment Advisers increased its stake in Cytokinetics by 12.4% in the 2nd quarter. Cetera Investment Advisers now owns 6,635 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 731 shares during the period. EverSource Wealth Advisors LLC increased its stake in Cytokinetics by 723.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 673 shares during the period. Gabelli Funds LLC lifted its holdings in Cytokinetics by 29.4% during the 2nd quarter. Gabelli Funds LLC now owns 8,410 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 1,910 shares in the last quarter. Finally, California Public Employees Retirement System boosted its position in Cytokinetics by 10.8% in the 2nd quarter. California Public Employees Retirement System now owns 142,602 shares of the biopharmaceutical company’s stock valued at $4,712,000 after buying an additional 13,911 shares during the period.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Needham raised its price target to $112 and reiterated a Buy rating, implying substantial upside and reinforcing the bullish analyst view of Cytokinetics’ pipeline and long-term prospects. Benzinga analyst rating report
• Positive Sentiment: For the second quarter of 2026, Cytokinetics reported a loss of $1.50 per share, narrower than the consensus loss estimate of $1.63. Revenue of $28.6 million also exceeded estimates of approximately $17.6 million. Cytokinetics second-quarter 2026 results
• Neutral Sentiment: The company ended the quarter with approximately $1.17 billion in cash and equivalents, providing funding for ongoing development and commercialization efforts. However, operating cash outflow was approximately $159.8 million.
• Negative Sentiment: Revenue fell 57.1% year over year, while Cytokinetics remained deeply unprofitable. The company posted a $179.2 million operating loss and a $198.8 million net loss attributable to common shareholders. Cytokinetics Q2 earnings analysis
• Negative Sentiment: Reported insider activity showed 49 sales and no purchases during the past six months, including selling by senior executives. Although insider sales can reflect compensation or planned transactions, the lack of purchases may weigh on sentiment.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.